About Us

Preclinical CRO In India

Vipragen, a renowned Contract Research Organization (CRO), offers comprehensive services for global Pharmaceutical, Biopharmaceutical, Chemical, Nutraceutical and Medical Device companies. With over 12 years of experience, Vipragen Biosciences Private Limited is dedicated to delivering quality services.

Under the leadership of Dr. Chandrashekaran Siddamadappa, Chairman and Managing Director, Vipragen has emerged as an Integrated Pre-clinical CRO, championing sustainability, integrity, safety and quality. Our state-of-the-art Vivarium holds Global certifications like OECD GLP, AAALAC and NABL, supported by multidisciplinary experts and equipped with 21CFR Part 11 compliance systems and processes. We ensure reliable data adhering to global standards with a focus on customer satisfaction. Our diverse portfolio includes Analytical, Toxicology and Chemistry services tailored to meet stringent regulatory submission requirements across the industries, ensuring compliance and transparency for clients across the industry spectrum.

Leadership

Dr. S Chandrashekaran

Chairman and Managing Director

Mr. Yashas Chandra

Director of Operations and Deputy TFM

Dr. Chaitra Harsha

Joint Managing Director

Dr. V. V. Vaidyanathan

Head Discovery Services

Dr. Pradeep Takawale

Head – Preclinical Services and TFM

Mr. Ramakrishna Dasoju

AVP Business Development

Mr. Saravanan Muthaiah

AVP Techno commercial Sales

Mr. Ashok Malavali

Vice President Business Development –
North America

Collaborations

Vipragen biosciences and global product compliance (gpc) forging alliance for integrated pre-clinical and regulatory solutions

Vipragen and GPC proudly announce a strategic partnership offering end-to-end research and regulatory solutions across diverse sectors in the European market. Leveraging Vipragen's drug discovery and preclinical CRO capabilities alongside GPC's regulatory study management expertise, this collaboration provides a comprehensive solution for product development to registration. Our core objective is to combine capabilities, attract a broader client base, and position ourselves as a leading CRO provider in Europe, catering to evolving global requirements. This partnership signifies an evolution in our capabilities, delivering integrated solutions on a global scale and advancing industry standards. We are excited about the possibilities this collaboration brings and look forward to shaping the future together, demonstrating our commitment to advancement. Stay tuned for updates as we embark on this journey, sharing the benefits with our valued clients and partners.

Vipragen biosciences and global product compliance (gpc) forging alliance for integrated pre-clinical and regulatory solutions

Vipragen and GPC proudly announce a strategic partnership offering end-to-end research and regulatory solutions across diverse sectors in the European market. Leveraging Vipragen's drug discovery and preclinical CRO capabilities alongside GPC's regulatory study management expertise, this collaboration provides a comprehensive solution for product development to registration. Our core objective is to combine capabilities, attract a broader client base, and position ourselves as a leading CRO provider in Europe, catering to evolving global requirements. This partnership signifies an evolution in our capabilities, delivering integrated solutions on a global scale and advancing industry standards. We are excited about the possibilities this collaboration brings and look forward to shaping the future together, demonstrating our commitment to advancement. Stay tuned for updates as we embark on this journey, sharing the benefits with our valued clients and partners.

Vipragen Biosciences Pvt Ltd and Mestastop® Solutions have signed an MoU to advance the discovery and development of effective anti-metastatic therapies. With metastasis being a leading cause of cancer-related death, this partnership aims to redefine the preclinical and clinical development paradigm by validating potential preclinical targets using appropriate models. Together, they strive to provide comprehensive solutions for successful development of anti-metastatic therapies, addressing the critical need in oncology drug development.

Vipragen Biosciences Pvt Ltd and Mestastop® Solutions have signed an MoU to advance the discovery and development of effective anti-metastatic therapies. With metastasis being a leading cause of cancer-related death, this partnership aims to redefine the preclinical and clinical development paradigm by validating potential preclinical targets using appropriate models. Together, they strive to provide comprehensive solutions for successful development of anti-metastatic therapies, addressing the critical need in oncology drug development.

 

Vipragen aims to partner with any Bio-innovators to co-develop molecules through unique technology platforms. Our collaborators can benefit from the advanced Artificial intelligence co-developers for smarter and faster drug discovery programs. Vipragen is also focused on Nextgen alternate to animal testing as a part of the cell-based safety pharmacology assays, that are being validated at a fast pace. Vipragen welcomes start-ups and sponsor collaborators to make the most of such platforms and constantly add value to research by effective delivery.

Vipragen Collaborates with JSS Medical College

Vipragen signs an MOU with the JSS group of Hospital Mysore which is a part of JSS Medical College for a strategic collaboration for looking at holistic approach to healthcare. Through the collaboration the two groups are poised to take on pressing challenge pertaining to gap between Preclinical Drug testing to clinical In-patient approach. In the vision to perform an end to end Drug Development possibility and provide the collaborative partner with a comprehensive solution from Lab to Market. It is an absolute honour to integrate with the prestigious premiere institute such as JSS to make the clinical testing more versatile, with integrated project and data management. With this collaboration, Vipragen is poised to address the growing need to make drug discovery and development affordable.

Vipragen Collaborates with JSS Medical College

Vipragen signs an MOU with the JSS group of Hospital Mysore which is a part of JSS Medical College for a strategic collaboration for looking at holistic approach to healthcare. Through the collaboration the two groups are poised to take on pressing challenge pertaining to gap between Preclinical Drug testing to clinical In-patient approach. In the vision to perform an end to end Drug Development possibility and provide the collaborative partner with a comprehensive solution from Lab to Market. It is an absolute honour to integrate with the prestigious premiere institute such as JSS to make the clinical testing more versatile, with integrated project and data management. With this collaboration, Vipragen is poised to address the growing need to make drug discovery and development affordable.

JNC Collaboration

Vipragen Biosciences has partnered with the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru to help to identify the drug candidates that could potentially cure neurodegenerative diseases (ND) such as Alzheimer’s and Parkinson’s. The research theorizes that the main cause of neurodegenerative diseases is an accumulation of toxic protein clumps inside neurons in aged individuals. However, these aggregates could be cleared using small molecules that accelerate an intracellular recycling mechanism called autophagy.

"We can use the proprietary platform to identify the new drug candidates for neurodegeneration" says Dr Chaitra Harsha, Joint MD, Vipragen Biosciences. The firm will carry forward testing of potential drugcandidates which showed promise in preclinical animal trials as part of a public-private partnership.

Read More

JNC Collaboration

Vipragen Biosciences has partnered with the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru to help to identify the drug candidates that could potentially cure neurodegenerative diseases (ND) such as Alzheimer’s and Parkinson’s. The research theorizes that the main cause of neurodegenerative diseases is an accumulation of toxic protein clumps inside neurons in aged individuals. However, these aggregates could be cleared using small molecules that accelerate an intracellular recycling mechanism called autophagy.

“We can use the proprietary platform to identify the new drug candidates for neurodegeneration” says Dr Chaitra Harsha, Joint MD, Vipragen Biosciences. The firm will carry forward testing of potential drugcandidates which showed promise in preclinical animal trials as part of a public-private partnership.

Read More

 

Vipragen and Transcell Collaboration

Vipragen in partnership with Transcell to offer an alternative Non-Human testing platforms for wide range of application. This collaboration allows the industry partners in the Pharma, Biopharma, Agrochemical and herbal space to enable a new platform discovery offerings which is integrated as a part of exploratory regime. Vipragen believes firmly in the 3Rs Approach – Reduction, Replacement and Refinement as a significant step to animal welfare principals, Transcell partnership will enable an alternative testing platforms which results in lower testing costs and time.

Vipragen now addresses the growing need for innovative alternative to Invivo Toxicity testing, as this partnership facilitates in human sourced primary, progenitor cell based platforms, the read outs would be a 100% physiologically relevant to human/patient conditions supporting industries across spectrum.

Vipragen and Transcell Collaboration

Vipragen in partnership with Transcell to offer an alternative Non-Human testing platforms for wide range of application. This collaboration allows the industry partners in the Pharma, Biopharma, Agrochemical and herbal space to enable a new platform discovery offerings which is integrated as a part of exploratory regime. Vipragen believes firmly in the 3Rs Approach – Reduction, Replacement and Refinement as a significant step to animal welfare principals, Transcell partnership will enable an alternative testing platforms which results in lower testing costs and time.

Vipragen now addresses the growing need for innovative alternative to Invivo Toxicity testing, as this partnership facilitates in human sourced primary, progenitor cell based platforms, the read outs would be a 100% physiologically relevant to human/patient conditions supporting industries across spectrum.

Know more in under Discovery Services.

Vipragen has performed Integrated Drug Discovery projects funded by BIRAC in collaboration with other partner organizations supported by BIRAC (DST, India government schemes) in exploring drug candidates to be implicated as therapeutics against oncology and autoimmune disorders. Vipragen has presented collaborative work in global symposiums.

Vipragen has performed Integrated Drug Discovery projects funded by BIRAC in collaboration with other partner organizations supported by BIRAC (DST, India government schemes) in exploring drug candidates to be implicated as therapeutics against oncology and autoimmune disorders. Vipragen has presented collaborative work in global symposiums.

Accolades

Vipragen is the Winner of Elevate 100

As a part of ELEVATE Program in 2017 and identified as one of the most innovative firms in the state, an initiative of the Department of Information Technology and Biotechnology, the Government of Karnataka aims to provide a comprehensive entrepreneurship platform for startups. The event was envisioned to provide startups with the necessary boost at various stages through funding or mentoring as key enablers. As a result of this Vipragen has completed the project aimed at using in vitro scaffold 3D culture cell models that can be used as alternatives for animal testing.

More info here: https://www.missionstartupkarnataka.org/?en